Dr. Maya D. Srinivasan, MD, MSc, is a Hematologist and Medical Oncologist specializing in the care of patients with lymphomas. Her clinical and research interests lie at the intersection of global health and oncology, with a strong commitment to reducing oncologic disparities worldwide. She is particularly focused on advancing care for patients with virally-mediated lymphomas, including Adult T-cell Leukemia/Lymphoma, EBV-associated lymphomas, and HIV-associated lymphomas. Dr. Srinivasan is dedicated to developing and expanding access to tolerable, effective, and novel therapeutic regimens, with the goal of improving outcomes and equity in lymphoma care globally.
Diversity, Equity, Inclusion and Accessibility
I deeply believe in our institutional mission to provide "exceptional care beyond exception." I am part of a dedicated team of healthcare trainees, professional, researchers, students and staff from different countries and various regions of the US and serve a similarly diverse patient population. The culture of our section is defined by the unique perspectives that each of us brings with us. As both a large academic medical center and safety-net hospital serving the communities of Boston and its surroundings, Boston Medical Center offers the unique opportunity to engage in cutting edge research and gain real-world clinical experience by caring for local and underserved populations. Our multilingual team is committed to promoting cultural competency, equity and inclusion in science, medicine and healthcare. We strive to maintain a workforce that is as diverse as the communities we serve and aim to create a safe space for our members to learn, grow and succeed in their life goals. Acknowledging that we all have a role to play, I am dedicated to welcoming and celebrating individuals of all races. ethnicities, social backgrounds, religion, gender, sex, age, ability, sexual orientation, veteran status, and national origin. I seek to promote DEIA principles by increasing clinical trial participation of our safety-net population and to better learn how to address sociocultural barriers to meet the diverse healthcare needs of our patients.
This tab shows grant data from BMC Sponsored Research. It includes:
- Grant title
- Project period and this person’s role on the grant
- PI name, if this person is not the PI (the name will link if PI has a BU Profile)
- Funding source(s). An arrow indicates the flow of funding if multiple sponsors.
- Some grants will show an agency award/project number, and may be a link.
- Data is sorted by project end date, and updated monthly.
This tab shows grant data from BU Sponsored Research. It includes:
- Grant title
- Project period and this person’s role on the grant
- PI name, if this person is not the PI (the name will link if PI has a BU Profile)
- Funding source(s). An arrow indicates the flow of funding if multiple sponsors.
- Some grants will show an agency award/project number, and may be a link.
- Data is sorted by project end date, and updated monthly.
This tab shows grant data that did not automatically get imported into Profiles
from BU or BMC sources.
- Grant title
- Project period and this person’s role on the grant
- PI name, if this person is not the PI (the name will link if PI has a BU Profile)
- Funding source(s). An arrow indicates the flow of funding if multiple sponsors.
- Some grants will show an agency award/project number, and may be a link.
- Data is sorted by project end date, and updated monthly.
This tab shows grant data from the Boston VA. We are only showing grant title, and only for people in the role of PI.
Study of Combination Regimen of Mogamulizumab and Lenalidomide in Relapsing/Refractory (r/r) Adult T-Cell Leukemia/Lymphoma (ATLL)10/16/2024 - 10/15/2026 (Subcontract PI)
PI:
Maya D. Srinivasan, MDThe Medical College of Virginia Foundation Bristol-Myers Sq Fdn
|
Yr
|
Title
|
Project-Sub Proj
|
Pubs
|
Publications listed below are automatically derived from MEDLINE/PubMed and other
sources, which might result in incorrect or missing publications. Faculty can
login
to make corrections and additions.
-
Dittus C, Weinstock MJ, Barnes J, Sandoval-Sus J, Grover NS, Beaven A, Hoye K, Shelton A, Tan X, Srinivasan MD, El-Jawahri A, Sarosiek S, Sloan JM. Final results of a multicentre pilot study evaluating brentuximab vedotin with cyclophosphamide, doxorubicin, etoposide and prednisone (BV-CHEP) for the treatment of aggressive adult T-cell leukaemia/lymphoma. Br J Haematol. 2025 Jun 03.View Related Profiles. PMID: 40459047; DOI: 10.1111/bjh.20177;
-
Bodanapu G, Corrigan J, Culnan J, Srinivasan M, Hora M, Lazzaro A, Yildirim C, Elbers D, Lang D, Do N, Brophy M, Bell B, Szalat RE, Munshi NC, Fillmore NR, Edwards CV. Risk Factors for Suboptimal Treatment in Patients with Newly Diagnosed Multiple Myeloma across US Healthcare Systems. Risk Factors for Suboptimal Treatment in Patients with Newly Diagnosed Multiple Myeloma across US Healthcare Systems. 2024; 144(Blood):3341. View Publication
-
Srinivasan MD, Dittus C, El-Jawahri A, Jain S, Shelton A, Sloan JM. Mogamulizumab Combinations in Patients with Relapsing/Refractory Adult T-Cell Leukemia/Lymphoma (r/r ATLL). Mogamulizumab Combinations in Patients with Relapsing/Refractory Adult T-Cell Leukemia/Lymphoma (r/r ATLL). 2024; 144(Blood):6405. View Publication
-
Abramson M, Glezerman IG, Srinivasan M, Ross R, Flombaum C, Gutgarts V. Hypophosphatemia and FGF23 tumor-induced osteomalacia in two cases of metastatic breast cancer. Clin Nephrol. 2021 Feb; 95(2):104-111. PMID: 33191899; PMCID: PMC8507415; DOI: 10.5414/CN110242;
-
Saggi SJ, Nath S, Culas R, Chittalae S, Burza A, Srinivasan M, Abdul R, Silver B, Lora A, Ibtida I, Chokshi T, Capric V, Mohamed A, Worah S, OuYang J, Geraghty P, Gruessner A, Salifu MO. Early Experience With Methylprednisolone on SARS-CoV-2 Infection in the African American Population, a Retrospective Analysis. Clin Med Insights Circ Respir Pulm Med. 2020; 14:1179548420980699. PMID: 33402859; PMCID: PMC7745550; DOI: 10.1177/1179548420980699;
This graph shows the total number of publications by year, by first, middle/unknown,
or last author.
| Year | Publications |
|---|
| 2020 | 1 |
| 2021 | 1 |
| 2024 | 2 |
| 2025 | 1 |
2020 SUNY Downstate Health Sciences Center:
Certificate of Courage Award
2020 Distinguished Covid-19 Frontline Service Award
2017 Arnold P. Gold Humanism Honor Society
2014-2018 Medical School Honor Society:
Cum Laude
2010 Finalist International Award for Excellence:
Global Studies Journal
2004 Selected for Pennsylvania Governor’s School for Information Technology